Surface coating of siRNA–peptidomimetic nano-self-assemblies with anionic lipid bilayers: enhanced gene silencing and reduced adverse effects in vitro
Source abstract
Abstract
Cationic vectors have demonstrated the potential to facilitate intracellular delivery of therapeutic oligonucleotides. However, enhanced transfection efficiency is usually associated with adverse effects, which also proves to be a challenge for vectors based on cationic peptides. In this study a series of proteolytically stable palmitoylated α-peptide/β-peptoid peptidomimetics with a systematically varied number of repeating lysine and homoarginine residues was shown to self-assemble with small interfering RNA (siRNA). The resulting well-defined nanocomplexes were coated with anionic lipids giving rise to net anionic liposomes. These complexes and the corresponding liposomes were optimized towards efficient gene silencing and low adverse effects. The optimal anionic liposomes mediated a high silencing effect, which was comparable to that of the control (cationic Lipofectamine 2000), and did not display any noticeable cytotoxicity and immunogenicity in vitro. In contrast, the corresponding nanocomplexes mediated a reduced silencing effect with a more narrow safety window. The surface coating with anionic lipid bilayers led to partial decomplexation of the siRNA-peptidomimetic nanocomplex core of the liposomes, which facilitated siRNA release. Additionally, the optimal anionic liposomes showed efficient intracellular uptake and endosomal escape. Therefore, these findings suggest that a more efficacious and safe formulation can be achieved by surface coating of the siRNA-peptidomimetic nano-self-assemblies with anionic lipid bilayers.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacy
Faculty of Health and Medical Sciences
University of Copenhagen
DK-2100 Copenhagen Ø, Denmark
Division of Immunology
Department of Infectious Diseases and Immunology
Faculty of Veterinary Medicine
Utrecht University
3584 CL Utrecht, The Netherlands
Department of Pharmaceutics
Department of Drug Design and Pharmacology
Funding
Seventh Framework Programme · Carlsbergfondet · Lundbeckfonden
References (32)
Show source-provided references
1. Lv · J. Controlled Release · 2006 · 114 · 10010.1016/j.jconrel.2006.04.014 ↗
2. Lächelt · Chem. Rev. · 2015 · 115 · 1104310.1021/cr5006793 ↗
3. Colombo · Expert Opin. Drug Delivery · 2014 · 11 · 148110.1517/17425247.2014.927439 ↗
4. Tagalakis · Biomaterials · 2014 · 35 · 840610.1016/j.biomaterials.2014.06.003 ↗
5. Foged · Biochim. Biophys. Acta · 2008 · 1778 · 248710.1016/j.bbamem.2008.06.020 ↗
6. Jing · Langmuir · 2012 · 28 · 516710.1021/la204033u ↗
7. Jing · Biochim. Biophys. Acta · 2012 · 1818 · 266010.1016/j.bbamem.2012.05.003 ↗
8. Tseng · Adv. Drug Delivery Rev. · 2009 · 61 · 72110.1016/j.addr.2009.03.003 ↗
9. Lee · J. Biol. Chem. · 1996 · 271 · 848110.1074/jbc.271.14.8481 ↗
10. Mignet · Int. J. Pharm. · 2008 · 361 · 19410.1016/j.ijpharm.2008.05.017 ↗
11. Kapoor · Int. J. Pharm. · 2012 · 432 · 8010.1016/j.ijpharm.2012.04.058 ↗
12. Lavigne · Expert Opin. Biol. Ther. · 2013 · 13 · 97310.1517/14712598.2013.743526 ↗
13. Ding · Nanotechnology · 2013 · 24 · 37510110.1088/0957-4484/24/37/375101 ↗
14. Nakamura · Acc. Chem. Res. · 2012 · 45 · 111310.1021/ar200254s ↗
15. Colombo · J. Controlled Release · 2013 · 166 · 22010.1016/j.jconrel.2013.01.006 ↗
16. Nakamura · J. Controlled. Release · 2007 · 119 · 36010.1016/j.jconrel.2007.03.010 ↗
17. Cun · Int. J. Pharm. · 2010 · 390 · 7010.1016/j.ijpharm.2009.10.023 ↗
18. Eirheim · Toxicol. In Vitro · 2004 · 18 · 64910.1016/j.tiv.2004.02.003 ↗
19. Lutz · J. Immunol. Methods · 1999 · 223 · 7710.1016/S0022-1759(98)00204-X ↗
20. Nordly · J. Controlled Release · 2011 · 150 · 30710.1016/j.jconrel.2010.11.021 ↗
21. van Asbeck · ACS Nano · 2013 · 7 · 379710.1021/nn305754c ↗
22. Hafez · Biochim. Biophys. Acta · 2000 · 1463 · 10710.1016/S0005-2736(99)00186-8 ↗
23. Ballarín-González · Adv. Drug Delivery Rev. · 2012 · 64 · 171710.1016/j.addr.2012.07.004 ↗
24. Torchilin · Proc. Natl. Acad. Sci. U. S. A. · 2003 · 100 · 197210.1073/pnas.0435906100 ↗
25. Lu · Mol. Pharm. · 2009 · 6 · 76310.1021/mp900023v ↗
26. Zeng · Biomaterials · 2014 · 35 · 122710.1016/j.biomaterials.2013.10.042 ↗
27. Whitehead · Nat. Rev. Drug Discovery · 2009 · 8 · 12910.1038/nrd2742 ↗
28. Hafez · Gene Ther. · 2001 · 8 · 118810.1038/sj.gt.3301506 ↗
29. Farhood · Biochim. Biophys. Acta · 1995 · 1235 · 28910.1016/0005-2736(95)80016-9 ↗
30. Hafez · Biochim. Biophys. Acta · 2000 · 1463 · 10710.1016/S0005-2736(99)00186-8 ↗
31. Li · J. Controlled Release · 2010 · 142 · 41610.1016/j.jconrel.2009.11.008 ↗
32. Mitsueda · Biopolymers · 2013 · 100 · 69810.1002/bip.22310 ↗